ScreenerHero

TXMD TherapeuticsMD, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · therapeuticsmd.com
2.000USD-0.99%Mkt Cap: 23.15M $P/E: —

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap23.15M USD
Enterprise Value19.75M USD
Revenue (TTM)3.27M USD
Gross Profit3.27M USD
Net Income (TTM)-569.00K USD
Revenue/Share0.28 USD
Last Price2.000 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)5.77
PEG—
EV/EBITDA-14.43
EV/Revenue6.04
P/S7.15
P/B0.87
EPS (TTM)-0.04
EPS (Forward)0.35
52W Range
0.990052% of range2.950
52W High2.950 USD
52W Low0.9900 USD
Profitability
Gross Margin100.00%
Oper. Margin-32.22%
EBITDA Margin-41.87%
Profit Margin-18.83%
ROE-2.12%
ROA-1.51%
Growth
Revenue Growth-8.70%
Earnings Growth-80.60%
Cash Flow & Leverage
Operating CF2.45M USD
CapEx (TTM)—
FCF Margin27.42%
FCF Yield3.87%
Net Debt-3.63M USD
Net Debt/EBITDA2.65
Balance Sheet
Debt/Equity0.23
Current Ratio3.22
Quick Ratio2.65
Book Value/Sh2.33 USD
Cash/Share0.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 9, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.57M
Float9.49M
Insiders9.04%
Institutions31.73%
Short Interest
Short Ratio0.8d
Short % Float0.32%
Short % Out.0.23%
Shares Short26.44K
Short (prev mo.)27.62K
Technical
SMA 502.109 (-5.2%)
SMA 2002.111 (-5.3%)
Beta0.65
S&P 52W Chg16.45%
Avg Vol (30d)21.11K
Avg Vol (10d)13.64K
Technical Indicators
RSI (14)39.2
MACD-0.0285
MACD Signal-0.0126
MACD Hist.-0.0159
BB Upper2.238 USD
BB Middle2.102 USD
BB Lower1.966 USD
BB Width12.96%
ATR (14)0.0686 USD
Vol Ratio (20d)2.88x